Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer
Lung cancer is one of the most common malignant tumours worldwide, with the highest mortality rate. Approximately 1.6 million deaths owing to lung cancer are reported annually; of which, 85% of deaths occur owing to non-small-cell lung cancer (NSCLC). At present, the conventional treatment methods f...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1120828/full |
| _version_ | 1811157785918832640 |
|---|---|
| author | Yu-Chen Yang Can-Jun Zhao Zhao-Feng Jin Jin Zheng Li-Tian Ma Li-Tian Ma |
| author_facet | Yu-Chen Yang Can-Jun Zhao Zhao-Feng Jin Jin Zheng Li-Tian Ma Li-Tian Ma |
| author_sort | Yu-Chen Yang |
| collection | DOAJ |
| description | Lung cancer is one of the most common malignant tumours worldwide, with the highest mortality rate. Approximately 1.6 million deaths owing to lung cancer are reported annually; of which, 85% of deaths occur owing to non-small-cell lung cancer (NSCLC). At present, the conventional treatment methods for NSCLC include radiotherapy, chemotherapy, targeted therapy and surgery. However, drug resistance and tumour invasion or metastasis often lead to treatment failure. The ubiquitin–proteasome pathway (UPP) plays an important role in the occurrence and development of tumours. Upregulation or inhibition of proteins or enzymes involved in UPP can promote or inhibit the occurrence and development of tumours, respectively. As regulators of UPP, ubiquitin-specific proteases (USPs) primarily inhibit the degradation of target proteins by proteasomes through deubiquitination and hence play a carcinogenic or anticancer role. This review focuses on the role of USPs in the occurrence and development of NSCLC and the potential of corresponding targeted drugs, PROTACs and small-molecule inhibitors in the treatment of NSCLC. |
| first_indexed | 2024-04-10T05:12:11Z |
| format | Article |
| id | doaj.art-f283386c12754fce9f8082be1369bc52 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T05:12:11Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-f283386c12754fce9f8082be1369bc522023-03-09T07:07:48ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.11208281120828Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancerYu-Chen Yang0Can-Jun Zhao1Zhao-Feng Jin2Jin Zheng3Li-Tian Ma4Li-Tian Ma5Department of Traditional Chinese Medicine, Tangdu Hospital, Air Force Medical University, Xi’an, ChinaDepartment of Traditional Chinese Medicine, Tangdu Hospital, Air Force Medical University, Xi’an, ChinaSchool of Psychology, Weifang Medical University, Weifang, ChinaDepartment of Traditional Chinese Medicine, Tangdu Hospital, Air Force Medical University, Xi’an, ChinaDepartment of Traditional Chinese Medicine, Tangdu Hospital, Air Force Medical University, Xi’an, ChinaDepartment of Gastroenterology, Tangdu Hospital, Air Force Medical University, Xi’an, ChinaLung cancer is one of the most common malignant tumours worldwide, with the highest mortality rate. Approximately 1.6 million deaths owing to lung cancer are reported annually; of which, 85% of deaths occur owing to non-small-cell lung cancer (NSCLC). At present, the conventional treatment methods for NSCLC include radiotherapy, chemotherapy, targeted therapy and surgery. However, drug resistance and tumour invasion or metastasis often lead to treatment failure. The ubiquitin–proteasome pathway (UPP) plays an important role in the occurrence and development of tumours. Upregulation or inhibition of proteins or enzymes involved in UPP can promote or inhibit the occurrence and development of tumours, respectively. As regulators of UPP, ubiquitin-specific proteases (USPs) primarily inhibit the degradation of target proteins by proteasomes through deubiquitination and hence play a carcinogenic or anticancer role. This review focuses on the role of USPs in the occurrence and development of NSCLC and the potential of corresponding targeted drugs, PROTACs and small-molecule inhibitors in the treatment of NSCLC.https://www.frontiersin.org/articles/10.3389/fonc.2023.1120828/fullNSCLCUSPsPROTACsE3 ligasesignalling pathway |
| spellingShingle | Yu-Chen Yang Can-Jun Zhao Zhao-Feng Jin Jin Zheng Li-Tian Ma Li-Tian Ma Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer Frontiers in Oncology NSCLC USPs PROTACs E3 ligase signalling pathway |
| title | Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer |
| title_full | Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer |
| title_fullStr | Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer |
| title_full_unstemmed | Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer |
| title_short | Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer |
| title_sort | targeted therapy based on ubiquitin specific proteases signalling pathways and e3 ligases in non small cell lung cancer |
| topic | NSCLC USPs PROTACs E3 ligase signalling pathway |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1120828/full |
| work_keys_str_mv | AT yuchenyang targetedtherapybasedonubiquitinspecificproteasessignallingpathwaysande3ligasesinnonsmallcelllungcancer AT canjunzhao targetedtherapybasedonubiquitinspecificproteasessignallingpathwaysande3ligasesinnonsmallcelllungcancer AT zhaofengjin targetedtherapybasedonubiquitinspecificproteasessignallingpathwaysande3ligasesinnonsmallcelllungcancer AT jinzheng targetedtherapybasedonubiquitinspecificproteasessignallingpathwaysande3ligasesinnonsmallcelllungcancer AT litianma targetedtherapybasedonubiquitinspecificproteasessignallingpathwaysande3ligasesinnonsmallcelllungcancer AT litianma targetedtherapybasedonubiquitinspecificproteasessignallingpathwaysande3ligasesinnonsmallcelllungcancer |